Switch theme
Sign up to access all valuation multiples
Biovica International AB is a biotech company. The company develops and commercializes blood-based diagnostic tests with biomarkers that improve the monitoring and evaluation of modern cancer treatments. The company promotes healthcare through collaboration with cancer institutes and pharmaceutical companies. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.
2009
26
LTM Revenue $1.0M
LTM EBITDA -$7.9M
$5.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biovica International has a last 12-month revenue (LTM) of $1.0M and a last 12-month EBITDA of -$7.9M.
In the most recent fiscal year, Biovica International achieved revenue of $0.9M and an EBITDA of -$8.1M.
Biovica International expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biovica International valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | XXX | $0.9M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $0.8M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 94% | XXX | XXX | XXX |
| EBITDA | -$7.9M | XXX | -$8.1M | XXX | XXX | XXX |
| EBITDA Margin | -770% | XXX | -892% | XXX | XXX | XXX |
| EBIT | -$8.6M | XXX | -$9.3M | XXX | XXX | XXX |
| EBIT Margin | -837% | XXX | -1023% | XXX | XXX | XXX |
| Net Profit | -$8.8M | XXX | -$9.2M | XXX | XXX | XXX |
| Net Margin | -850% | XXX | -1017% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Biovica International's stock price is SEK 1 (or $0).
Biovica International has current market cap of SEK 69.1M (or $7.3M), and EV of SEK 49.3M (or $5.2M).
See Biovica International trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.2M | $7.3M | XXX | XXX | XXX | XXX | $-0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Biovica International has market cap of $7.3M and EV of $5.2M.
Biovica International's trades at 6.0x EV/Revenue multiple, and -0.6x EV/EBITDA.
Equity research analysts estimate Biovica International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biovica International has a P/E ratio of -0.8x.
See valuation multiples for Biovica International and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.3M | XXX | $7.3M | XXX | XXX | XXX |
| EV (current) | $5.2M | XXX | $5.2M | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | 6.0x | XXX | XXX | XXX |
| EV/EBITDA | -0.7x | XXX | -0.6x | XXX | XXX | XXX |
| EV/EBIT | -0.6x | XXX | -0.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.8x | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiovica International's last 12 month revenue growth is 72%
Biovica International's revenue per employee in the last FY averaged $35K, while opex per employee averaged $0.4M for the same period.
Biovica International's rule of 40 is -1022% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biovica International's rule of X is -591% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biovica International and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 72% | XXX | 66% | XXX | XXX | XXX |
| EBITDA Margin | -770% | XXX | -1094% | XXX | XXX | XXX |
| EBITDA Growth | -10% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1022% | XXX | -1022% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -591% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $35K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1116% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biovica International acquired XXX companies to date.
Last acquisition by Biovica International was XXXXXXXX, XXXXX XXXXX XXXXXX . Biovica International acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biovica International founded? | Biovica International was founded in 2009. |
| Where is Biovica International headquartered? | Biovica International is headquartered in Sweden. |
| How many employees does Biovica International have? | As of today, Biovica International has 26 employees. |
| Who is the CEO of Biovica International? | Biovica International's CEO is Mr. Anders Rylander. |
| Is Biovica International publicy listed? | Yes, Biovica International is a public company listed on STO. |
| What is the stock symbol of Biovica International? | Biovica International trades under BIOVIC B ticker. |
| When did Biovica International go public? | Biovica International went public in 2017. |
| Who are competitors of Biovica International? | Similar companies to Biovica International include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Biovica International? | Biovica International's current market cap is $7.3M |
| What is the current revenue of Biovica International? | Biovica International's last 12 months revenue is $1.0M. |
| What is the current revenue growth of Biovica International? | Biovica International revenue growth (NTM/LTM) is 72%. |
| What is the current EV/Revenue multiple of Biovica International? | Current revenue multiple of Biovica International is 5.0x. |
| Is Biovica International profitable? | Yes, Biovica International is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biovica International? | Biovica International's last 12 months EBITDA is -$7.9M. |
| What is Biovica International's EBITDA margin? | Biovica International's last 12 months EBITDA margin is -770%. |
| What is the current EV/EBITDA multiple of Biovica International? | Current EBITDA multiple of Biovica International is -0.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
